Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).

Status: No longer recruiting

Protocol number: ML20090

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A prospective, open label study of the effect of PEGASYS and ribavirin on quality of life, resource use and clinical outcomes in patients with chronic hepatitis C

Brief summary: This study will examine quality of life, resource use and clinical outcomes (primarily sustained virological response) in patients with CHC eligible to receive treatment with commercially available PEGASYS and ribavirin. The anticipated time on study treatment is 24 weeks for patients with genotypes 2 and 3, and 48 weeks for non-genotypes 2 and 3 (with outcome assessments made 24 weeks after treatment). The target sample size is 500 individuals. Target sample size is 500.

Study phase: IV

Study type: Interventional; Treatment; Non-Randomized; Open Label; Uncontrolled; Single Group; Safety/Efficacy study

Condition: Hepatitis C, Chronic

Intervention type: Drug

Intervention name: peginterferon alfa-2a (40KD) [PEGASYS]

Primary outcome: Sustained virological reponse Time frame:At end of treatment-free follow up.

Key secondary outcomes: Quality of life (SF-36), resource utilization, adverse events, labs. Time frame: Throughout study

Inclusion criteria:

  • males or females, >= 18 years of age;
  • CHC infection;
  • eligible for, and scheduled to receive, treatment with commercially available PEGASYS and ribavirin.

Exclusion criteria:

  • coinfection with hepatitis B or HIV;
  • moderate hepatic failure, decompensated cirrhosis or hepatocellular cancer;
  • known hypersensitivity to alfa interferons.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: March, 2006

Trial registration date: 05/04/2006

Date last updated: 9/29/2008


Link to trial result

This trial was conducted at the following locations:

Canada

  • Calgary, AB
  • Edmonton, AB
  • Abbotsford, BC
  • Surrey, BC
  • Vancouver, BC
  • Vernon, BC
  • West Vancouver, BC
  • Winnipeg, MB
  • Barrie, ON
  • Brampton, ON
  • Downsview, ON
  • Hamilton, ON
  • Kingston, ON
  • London, ON
  • Mississauga, ON
  • Newmarket, ON
  • Oshawa, ON
  • Ottawa, ON
  • Richmond Hill, ON
  • Sudbury, ON
  • Thunder Bay, ON
  • Toronto, ON
  • Whitby, ON
  • Windsor, ON
  • Montreal, QC
  • Quebec City, QC
  • St-Charles Borromee, QC
  • Regina, SK

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply